- Home
- SYRE vs PAXS Comparison
SYRE vs PAXS Comparison
Compare SYRE & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- PAXS
- Stock Information
- Founded
- SYRE 2013
- PAXS 2021
- Country
- SYRE United States
- PAXS United States
- Employees
- SYRE N/A
- PAXS N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- PAXS Investment Managers
- Sector
- SYRE Health Care
- PAXS Finance
- Exchange
- SYRE Nasdaq
- PAXS Nasdaq
- Market Cap
- SYRE 841.4M
- PAXS 677.7M
- IPO Year
- SYRE 2016
- PAXS N/A
- Fundamental
- Price
- SYRE $15.72
- PAXS $15.09
- Analyst Decision
- SYRE Buy
- PAXS
- Analyst Count
- SYRE 6
- PAXS 0
- Target Price
- SYRE $55.00
- PAXS N/A
- AVG Volume (30 Days)
- SYRE 673.0K
- PAXS 195.0K
- Earning Date
- SYRE 08-06-2025
- PAXS 01-01-0001
- Dividend Yield
- SYRE N/A
- PAXS 11.72%
- EPS Growth
- SYRE N/A
- PAXS N/A
- EPS
- SYRE N/A
- PAXS N/A
- Revenue
- SYRE N/A
- PAXS N/A
- Revenue This Year
- SYRE N/A
- PAXS N/A
- Revenue Next Year
- SYRE N/A
- PAXS N/A
- P/E Ratio
- SYRE N/A
- PAXS N/A
- Revenue Growth
- SYRE N/A
- PAXS N/A
- 52 Week Low
- SYRE $10.91
- PAXS $12.57
- 52 Week High
- SYRE $40.26
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- SYRE 51.34
- PAXS 49.31
- Support Level
- SYRE $14.97
- PAXS $15.05
- Resistance Level
- SYRE $16.92
- PAXS $15.19
- Average True Range (ATR)
- SYRE 1.12
- PAXS 0.09
- MACD
- SYRE 0.02
- PAXS 0.00
- Stochastic Oscillator
- SYRE 58.05
- PAXS 39.13
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.